SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharmas upcoming Phase 3 APPROACH topline readout for HLP003 in adjunctive major depressive disorder is the dominant focus, with traders treating the results as a high-stakes catalyst. Bulls emphasize the treatments add-on design and potential advantages, while skeptics question whether efficacy will hold up in Phase 3 and raise concerns about dilution and execution.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer, saying the application lacked statistically significant overall-survival evidence despite a strong progression-free-survival result. Traders view the decision as a setback, but debate whether it is limited to that indication or undermines the broader thesis, which many say now hinges on the HARMONi-3 first-line lung cancer readout.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound dominate discussion, with traders debating whether heavy selling and liquidations have exhausted themselves or signal further downside. Some attribute pressure to broader risk-off conditions, ETF outflows, and Binance-related concerns, while others view oversold technical readings and support as signs of a possible bounce.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00312867 USD and is down -5.82 over the last 24 hours. It is currently trading on 374 active market(s) with $10,034,947.48 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMYs prolonged decline toward recent lows is fueling debate, with some holders continuing to buy the dip while critics cite weak execution and the teams apparent focus on Janction (JCT) as reasons for the tokens underperformance. Some traders also point to broader crypto-market weakness, but the dominant conversation is frustration over JASMYs price action versus optimism about a possible recovery.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention ahead of its quarterly earnings report, with traders weighing a recent share-price rally against concerns about weak home-improvement demand, falling customer transactions, and high borrowing costs. The debate centers on whether resilient spending per visit and managements outlook can offset a sluggish housing market; options activity also reflects uncertainty about the earnings reaction.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is drawing attention amid sharp swings in South Korean equities, which traders link to selling in AI and memory-chip shares and the unwinding of leveraged positions. The community is split between warnings that forced selling and concentrated chip exposure could prolong the decline and dip buyers who see resilient memory demand and low valuations as support for a rebound.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.14666837 USD and is down -12.66 over the last 24 hours. It is currently trading on 1753 active market(s) with $480,085,527.58 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

Cardanos sharp decline has intensified bearish concern, with traders linking fears of a fading project to Charles Hoskinsons comments that the networks roadmap is complete and governance has shifted to the community. Some interpret this as abandonment, while supporters argue the infrastructure is finished and future growth depends on ecosystem builders; others see the selloff as a buying opportunity.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,699,860,951.91490568 with 589,238,106,731,035.4551592 in circulation. The last known price of Shiba Inu is 0.00000379 USD and is down -10.85 over the last 24 hours. It is currently trading on 1128 active market(s) with $78,538,817.41 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIBs weak, choppy trading and continued decline are drawing attention, with traders pointing to bearish chart signals and waning meme-coin hype. Frustrated holders see more downside, while some dip buyers remain hopeful for a recovery or renewed rally.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Positive interim REGAIN data in recurrent glioblastoma is driving attention, with traders emphasizing the reported tumor responses and survival results. Enthusiasm is tempered by the small early cohort, and the community is looking for more detail on durability, safety, and the potential path toward a market submission.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a broad crypto selloff and a steep decline that traders say has pushed it toward multi-year lows. The community is split between buying the dip and expecting further losses, with many linking DOGEs weakness to Bitcoin and the wider market.

statis crypto Watchlist

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FAQ for $RVNC investors  
 
Q:What is this settlement about? 
 
A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer.  
 
Q: Who may qualify? 
 
A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025.  
 
Q: What’s the deadline? 
 
A: The claim deadline is Aug. 28, 2026.  
 
Q: What happened to the stock? 
 
A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share.  
 
Q: Is my data safe with 11th Estate?  
 
A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. 
 
Q: What is the fee?  
 
A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don&#39;t get a payout, you don&#39;t pay us a cent. 
 
Q: How do I start?  
 
A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement

Revance Therapeutics has agreed to a tentative settlement to resolve investor claims tied to its Teoxane dispute, delayed Crown tender offer, and related sto...

11th.com

Revance Therapeutics ($RVNC) Investor Settlement

StockTwits Web

Revance Therapeutics Inc

 investors  
 
Q:What is this settlement about? 
 
A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer.  
 
Q: Who may qualify? 
 
A: Investors who purchased or acquired 

 securities between Feb. 29, 2024 and Feb. 6, 2025.  
 
Q: What’s the deadline? 
 
A: The claim deadline is Aug. 28, 2026.  
 
Q: What happened to the stock? 
 
A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share.  
 
Q: Is my data safe with 11th Estate?  
 
A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. 
 
Q: What is the fee?  
 
A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. 
 
Q: How do I start?  
 
A: Just click the link below to submit your claim through our secure portal. 